"rationale","id","name","description","label","instanceType","uuid:ID"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","Study Design 1","The main design for the study","","StudyDesign","a3add560-64ed-49b9-b312-91e13be67a1b"
